- Home
- AVXL vs CVAC Comparison
AVXL vs CVAC Comparison
Compare AVXL & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVXL
- CVAC
- Stock Information
- Founded
- AVXL 2004
- CVAC 2000
- Country
- AVXL United States
- CVAC Germany
- Employees
- AVXL N/A
- CVAC N/A
- Industry
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- AVXL Health Care
- CVAC Health Care
- Exchange
- AVXL Nasdaq
- CVAC Nasdaq
- Market Cap
- AVXL 710.3M
- CVAC 764.4M
- IPO Year
- AVXL N/A
- CVAC 2020
- Fundamental
- Price
- AVXL $9.09
- CVAC $5.44
- Analyst Decision
- AVXL Strong Buy
- CVAC Buy
- Analyst Count
- AVXL 2
- CVAC 3
- Target Price
- AVXL $44.00
- CVAC $9.00
- AVG Volume (30 Days)
- AVXL 768.8K
- CVAC 2.1M
- Earning Date
- AVXL 08-05-2025
- CVAC 08-14-2025
- Dividend Yield
- AVXL N/A
- CVAC N/A
- EPS Growth
- AVXL N/A
- CVAC N/A
- EPS
- AVXL N/A
- CVAC 0.87
- Revenue
- AVXL N/A
- CVAC $566,039,775.00
- Revenue This Year
- AVXL N/A
- CVAC N/A
- Revenue Next Year
- AVXL N/A
- CVAC $24.04
- P/E Ratio
- AVXL N/A
- CVAC $6.34
- Revenue Growth
- AVXL N/A
- CVAC 787.60
- 52 Week Low
- AVXL $3.76
- CVAC $2.37
- 52 Week High
- AVXL $14.44
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- AVXL 64.24
- CVAC 68.03
- Support Level
- AVXL $7.97
- CVAC $4.07
- Resistance Level
- AVXL $9.35
- CVAC $5.58
- Average True Range (ATR)
- AVXL 0.38
- CVAC 0.20
- MACD
- AVXL 0.18
- CVAC 0.07
- Stochastic Oscillator
- AVXL 86.10
- CVAC 83.08
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.